Apoptosis induced by piroxicam plus cisplatin combined treatment is triggered by p21 in mesothelioma

Alfonso Baldi, Maria Teresa Piccolo, Maria Rosaria Boccellino, Aldo Donizetti, Irene Cardillo, Raffaele Porta, Lucio Quagliuolo, Enrico P. Spugnini, Francesca Cordero, Gennaro Citro, Massimo Menegozzo, Raffaele A. Calogero, Stefania Crispi

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Background: Malignant mesothelioma (MM) is a rare, highly aggressive tumor, associated to asbestos exposure. To date no chemotherapy regimen for MM has proven to be definitively curative, and new therapies for MM treatment need to be developed. We have previously shown in vivo that piroxicam/cisplatin combined treatment in MM, specifically acts on cell cycle regulation triggering apoptosis, with survival increase. Methodology/Principal Findings: We analyzed, at molecular level, the apoptotic increase caused by piroxicam/cisplatin treatment in MM cell lines. By means of genome wide analyses, we analyzed transcriptional gene deregulation both after the single piroxicam or cisplatin and the combined treatment. Here we show that apoptotic increase following combined treatment is mediated by p21, since apoptotic increase in piroxicam/cisplatin combined treatment is abolished upon p21 silencing. Conclusions/Significance: Piroxicam/cisplatin combined treatment determines an apoptosis increase in MM cells, which is dependent on the p21 expression. The results provided suggest that piroxicam/cisplatin combination might be tested in clinical settings in tumor specimens that express p21.

Original languageEnglish
Article numbere23569
JournalPLoS One
Volume6
Issue number8
DOIs
Publication statusPublished - 2011

Fingerprint

mesothelioma
Piroxicam
cisplatin
Mesothelioma
Cisplatin
apoptosis
Apoptosis
Tumors
Therapeutics
Genes
Cells
asbestos
neoplasms
Chemotherapy
Deregulation
Asbestos
drug therapy
cell cycle
cell lines
Malignant Mesothelioma

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Baldi, A., Piccolo, M. T., Boccellino, M. R., Donizetti, A., Cardillo, I., Porta, R., ... Crispi, S. (2011). Apoptosis induced by piroxicam plus cisplatin combined treatment is triggered by p21 in mesothelioma. PLoS One, 6(8), [e23569]. https://doi.org/10.1371/journal.pone.0023569

Apoptosis induced by piroxicam plus cisplatin combined treatment is triggered by p21 in mesothelioma. / Baldi, Alfonso; Piccolo, Maria Teresa; Boccellino, Maria Rosaria; Donizetti, Aldo; Cardillo, Irene; Porta, Raffaele; Quagliuolo, Lucio; Spugnini, Enrico P.; Cordero, Francesca; Citro, Gennaro; Menegozzo, Massimo; Calogero, Raffaele A.; Crispi, Stefania.

In: PLoS One, Vol. 6, No. 8, e23569, 2011.

Research output: Contribution to journalArticle

Baldi, A, Piccolo, MT, Boccellino, MR, Donizetti, A, Cardillo, I, Porta, R, Quagliuolo, L, Spugnini, EP, Cordero, F, Citro, G, Menegozzo, M, Calogero, RA & Crispi, S 2011, 'Apoptosis induced by piroxicam plus cisplatin combined treatment is triggered by p21 in mesothelioma', PLoS One, vol. 6, no. 8, e23569. https://doi.org/10.1371/journal.pone.0023569
Baldi, Alfonso ; Piccolo, Maria Teresa ; Boccellino, Maria Rosaria ; Donizetti, Aldo ; Cardillo, Irene ; Porta, Raffaele ; Quagliuolo, Lucio ; Spugnini, Enrico P. ; Cordero, Francesca ; Citro, Gennaro ; Menegozzo, Massimo ; Calogero, Raffaele A. ; Crispi, Stefania. / Apoptosis induced by piroxicam plus cisplatin combined treatment is triggered by p21 in mesothelioma. In: PLoS One. 2011 ; Vol. 6, No. 8.
@article{ccf276ec378a447f94eb538f3969e832,
title = "Apoptosis induced by piroxicam plus cisplatin combined treatment is triggered by p21 in mesothelioma",
abstract = "Background: Malignant mesothelioma (MM) is a rare, highly aggressive tumor, associated to asbestos exposure. To date no chemotherapy regimen for MM has proven to be definitively curative, and new therapies for MM treatment need to be developed. We have previously shown in vivo that piroxicam/cisplatin combined treatment in MM, specifically acts on cell cycle regulation triggering apoptosis, with survival increase. Methodology/Principal Findings: We analyzed, at molecular level, the apoptotic increase caused by piroxicam/cisplatin treatment in MM cell lines. By means of genome wide analyses, we analyzed transcriptional gene deregulation both after the single piroxicam or cisplatin and the combined treatment. Here we show that apoptotic increase following combined treatment is mediated by p21, since apoptotic increase in piroxicam/cisplatin combined treatment is abolished upon p21 silencing. Conclusions/Significance: Piroxicam/cisplatin combined treatment determines an apoptosis increase in MM cells, which is dependent on the p21 expression. The results provided suggest that piroxicam/cisplatin combination might be tested in clinical settings in tumor specimens that express p21.",
author = "Alfonso Baldi and Piccolo, {Maria Teresa} and Boccellino, {Maria Rosaria} and Aldo Donizetti and Irene Cardillo and Raffaele Porta and Lucio Quagliuolo and Spugnini, {Enrico P.} and Francesca Cordero and Gennaro Citro and Massimo Menegozzo and Calogero, {Raffaele A.} and Stefania Crispi",
year = "2011",
doi = "10.1371/journal.pone.0023569",
language = "English",
volume = "6",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "8",

}

TY - JOUR

T1 - Apoptosis induced by piroxicam plus cisplatin combined treatment is triggered by p21 in mesothelioma

AU - Baldi, Alfonso

AU - Piccolo, Maria Teresa

AU - Boccellino, Maria Rosaria

AU - Donizetti, Aldo

AU - Cardillo, Irene

AU - Porta, Raffaele

AU - Quagliuolo, Lucio

AU - Spugnini, Enrico P.

AU - Cordero, Francesca

AU - Citro, Gennaro

AU - Menegozzo, Massimo

AU - Calogero, Raffaele A.

AU - Crispi, Stefania

PY - 2011

Y1 - 2011

N2 - Background: Malignant mesothelioma (MM) is a rare, highly aggressive tumor, associated to asbestos exposure. To date no chemotherapy regimen for MM has proven to be definitively curative, and new therapies for MM treatment need to be developed. We have previously shown in vivo that piroxicam/cisplatin combined treatment in MM, specifically acts on cell cycle regulation triggering apoptosis, with survival increase. Methodology/Principal Findings: We analyzed, at molecular level, the apoptotic increase caused by piroxicam/cisplatin treatment in MM cell lines. By means of genome wide analyses, we analyzed transcriptional gene deregulation both after the single piroxicam or cisplatin and the combined treatment. Here we show that apoptotic increase following combined treatment is mediated by p21, since apoptotic increase in piroxicam/cisplatin combined treatment is abolished upon p21 silencing. Conclusions/Significance: Piroxicam/cisplatin combined treatment determines an apoptosis increase in MM cells, which is dependent on the p21 expression. The results provided suggest that piroxicam/cisplatin combination might be tested in clinical settings in tumor specimens that express p21.

AB - Background: Malignant mesothelioma (MM) is a rare, highly aggressive tumor, associated to asbestos exposure. To date no chemotherapy regimen for MM has proven to be definitively curative, and new therapies for MM treatment need to be developed. We have previously shown in vivo that piroxicam/cisplatin combined treatment in MM, specifically acts on cell cycle regulation triggering apoptosis, with survival increase. Methodology/Principal Findings: We analyzed, at molecular level, the apoptotic increase caused by piroxicam/cisplatin treatment in MM cell lines. By means of genome wide analyses, we analyzed transcriptional gene deregulation both after the single piroxicam or cisplatin and the combined treatment. Here we show that apoptotic increase following combined treatment is mediated by p21, since apoptotic increase in piroxicam/cisplatin combined treatment is abolished upon p21 silencing. Conclusions/Significance: Piroxicam/cisplatin combined treatment determines an apoptosis increase in MM cells, which is dependent on the p21 expression. The results provided suggest that piroxicam/cisplatin combination might be tested in clinical settings in tumor specimens that express p21.

UR - http://www.scopus.com/inward/record.url?scp=80051815813&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051815813&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0023569

DO - 10.1371/journal.pone.0023569

M3 - Article

VL - 6

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 8

M1 - e23569

ER -